 |
| Attached files |
| File | Filename |
|---|
| EX-31.2 - EXHIBIT 31.2 - ONCOVISTA INNOVATIVE THERAPIES, INC | v306005_ex31-2.htm |
| XML - IDEA: XBRL DOCUMENT - ONCOVISTA INNOVATIVE THERAPIES, INC | R2.htm |
| XML - IDEA: XBRL DOCUMENT - ONCOVISTA INNOVATIVE THERAPIES, INC | R20.htm |
| XML - IDEA: XBRL DOCUMENT - ONCOVISTA INNOVATIVE THERAPIES, INC | R10.htm |
| XML - IDEA: XBRL DOCUMENT - ONCOVISTA INNOVATIVE THERAPIES, INC | R5.htm |
| XML - IDEA: XBRL DOCUMENT - ONCOVISTA INNOVATIVE THERAPIES, INC | R21.htm |
| XML - IDEA: XBRL DOCUMENT - ONCOVISTA INNOVATIVE THERAPIES, INC | R16.htm |
| XML - IDEA: XBRL DOCUMENT - ONCOVISTA INNOVATIVE THERAPIES, INC | R14.htm |
| XML - IDEA: XBRL DOCUMENT - ONCOVISTA INNOVATIVE THERAPIES, INC | R15.htm |
| XML - IDEA: XBRL DOCUMENT - ONCOVISTA INNOVATIVE THERAPIES, INC | R19.htm |
| XML - IDEA: XBRL DOCUMENT - ONCOVISTA INNOVATIVE THERAPIES, INC | R11.htm |
| XML - IDEA: XBRL DOCUMENT - ONCOVISTA INNOVATIVE THERAPIES, INC | R12.htm |
| XML - IDEA: XBRL DOCUMENT - ONCOVISTA INNOVATIVE THERAPIES, INC | R4.htm |
| XML - IDEA: XBRL DOCUMENT - ONCOVISTA INNOVATIVE THERAPIES, INC | R18.htm |
| XML - IDEA: XBRL DOCUMENT - ONCOVISTA INNOVATIVE THERAPIES, INC | R1.htm |
| XML - IDEA: XBRL DOCUMENT - ONCOVISTA INNOVATIVE THERAPIES, INC | R17.htm |
| XML - IDEA: XBRL DOCUMENT - ONCOVISTA INNOVATIVE THERAPIES, INC | R3.htm |
| XML - IDEA: XBRL DOCUMENT - ONCOVISTA INNOVATIVE THERAPIES, INC | R7.htm |
| XML - IDEA: XBRL DOCUMENT - ONCOVISTA INNOVATIVE THERAPIES, INC | R22.htm |
| XML - IDEA: XBRL DOCUMENT - ONCOVISTA INNOVATIVE THERAPIES, INC | R6.htm |
| XML - IDEA: XBRL DOCUMENT - ONCOVISTA INNOVATIVE THERAPIES, INC | R8.htm |
| EXCEL - IDEA: XBRL DOCUMENT - ONCOVISTA INNOVATIVE THERAPIES, INC | Financial_Report.xls |
| XML - IDEA: XBRL DOCUMENT - ONCOVISTA INNOVATIVE THERAPIES, INC | R9.htm |
| EX-32 - EXHIBIT 32 - ONCOVISTA INNOVATIVE THERAPIES, INC | v306005_ex32.htm |
| EX-31.1 - EXHIBIT 31.1 - ONCOVISTA INNOVATIVE THERAPIES, INC | v306005_ex31-1.htm |
| 10-K - FORM 10-K - ONCOVISTA INNOVATIVE THERAPIES, INC | v306005_10k.htm |
v2.4.0.6
|
DEBT
|
12 Months Ended |
|
Dec. 31, 2011
|
| Debt Disclosure [Abstract] |
|
| Debt Disclosure [Text Block] |
Note 6. DEBT
As a result of the Stock Purchase Agreement with Alere Holdings, the Company has eliminated substantially all of its outstanding debt using a portion of the Company’s share of proceeds received from the initial milestone payment under the Stock Purchase Agreement. In connection with the Stock Purchase Agreement, the Company’s contingently redeemable shares were issued and subsequently sold to Alere Holdings. The Company also repaid the principal and accrued interest to the holders of the 2009 Bridge Note, as well as the loans and advances from Alexander L. Weis, Ph.D., Chairman of the Company’s board of directors and its CEO, President, CFO and Secretary, and a significant shareholder (the “CEO”) and affiliates of the CEO.
The Company had the following outstanding loans and notes payable at December 31, 2011 and 2010:
| |
|
2011 |
|
|
2010 |
|
| Unsecured convertible notes payable to a third party with interest at 8% and due on demand, matured in December 2005 (1) |
|
$ |
100,000 |
|
|
$ |
100,000 |
|
| Total notes payable |
|
|
100,000 |
|
|
|
100,000 |
|
| Less: current portion |
|
|
(100,000 |
) |
|
|
(100,000 |
) |
| Total long-term debt |
|
$ |
– |
|
|
$ |
– |
|
| |
(1) |
The debt holder, at its option, may convert the principal and any accrued interest into shares of common stock at a price of $2.50 per share. The Company is currently in default. |
|
| X |
- Details
| Name: |
us-gaap_DebtDisclosureAbstract |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:stringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19,20,22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 129
-Paragraph 2, 4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 19, 20, 22
-Article 5
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644
+ Details
| Name: |
us-gaap_DebtDisclosureTextBlock |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
nonnum:textBlockItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
This web site and associated pages are not associated with, endorsed by, or sponsored by ONCOVISTA INNOVATIVE THERAPIES, INC and has no official or unofficial affiliation with ONCOVISTA INNOVATIVE THERAPIES, INC
Based on public records. Inadvertent errors are possible.
Faqs.org does not guarantee the accuracy or timeliness of any information on this site. Use at your own risk.
This website is not associated with the SEC
Some parts © 2013 Advameg, Inc.
|
|
